Research Insights on Tuberculosis - Pipeline Review, H2 2016
Tuberculosis - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.
Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.
To access full report with TOC, please visit Tuberculosis - Pipeline Review, H2 2016
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Tuberculosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 7, 8, 61, 37 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 4, 5, 35 and 37 molecules, respectively.Tuberculosis.
Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)
- The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Abera Bioscience AB Akthelia Pharmaceuticals Limited Alvogen Korea Co., Ltd. Anacor Pharmaceuticals, Inc. Archivel Farma S.L. AstraZeneca Plc Beech Tree Labs, Inc. BioDiem Ltd BioLingus AG Biomar Microbial Technologies Bioversys AG Celgene Corporation Cellceutix Corporation Chongqing Zhifei Biological Products Co., Ltd. Crestone, Inc. Dafra Pharma International Ltd. Daiichi Sankyo Company, Limited Demuris Limited Eisai Co., Ltd. Eli Lilly and Company Ensol Biosciences Inc. EpiVax, Inc. FIT Biotech Oy GangaGen Inc. GlaxoSmithKline Plc Globeimmune, Inc. Hager Biosciences, LLC Hsiri Therapeutics LLC Imaxio SA Immunitor, Inc. ImmunoBiology Limited Inovio Pharmaceuticals, Inc. Johnson & Johnson Lakewood-Amedex Inc Lipotek Pty Ltd. Matinas BioPharma Holdings, Inc. Microbion Corporation Microbiotix, Inc. NEARMEDIC PLUS, Ltd Novartis AG NovoBiotic Pharmaceuticals, LLC Otsuka Holdings Co., Ltd. QureTech Bio AB Recce Pty Ltd Rodos BioTarget GmbH Sanofi Sanofi Pasteur SA Sarepta Therapeutics, Inc. Sequella, Inc. Shionogi & Co., Ltd. Sphaera Pharma Pvt. Ltd. Spring Bank Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited TetraLogic Pharmaceuticals TGV-Laboratories Theravectys SA Tomegavax, Inc. Transgene SA TVAX Biomedical, Inc. Univalue Valorizacion, S.L. Vaccibody AS Vakzine Projekt Management GmbH Vaxil Bio Therapeutics Ltd. Vichem Chemie Research Ltd.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 23:32
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home